Absence of p53 protein overexpression in precancerous lesions of the vulva

Cancer

Volumn 82, Issue 2, 1998, Pages 323-327

  Kohlberger, Petra D ^a   Kirnbauer, Reinhard ^b   Bancher, Dagmar ^a   Gitsch, Gerald ^a   Reinthaller, Alexander ^a   Leodolter, Sepp ^c   Tschachler, Erwin ^b   Kainz, Christian ^a   Breitenecker, Gerhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c Ludwig Boltzmann Society   (Austria)

Author keywords

Human papillomavirus (HPV); Immunohistochemistry; p53; Polymerase chain reaction; Vulvar intraepithelial neoplasia

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INVASION; CARCINOMA IN SITU; CLINICAL ARTICLE; DYSPLASIA; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS INFECTION; VULVA CARCINOMA; WART VIRUS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOPSY; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, VIRAL; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS; VULVAR NEOPLASMS; WARTS;

EID: 0031975084     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980115)82:2<328::AID-CNCR12>3.0.CO;2-0     Document Type: Article

References (30)

1. Kurman RJ, Toki T, Schiffman MH. Basaloid and warty carcinoma of the vulva. Am J Surg Pathol 1993;17:133-45.
2. Trimble CL, Hildesheim A, Brinton LA, Shah KV, Kurman RJ. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol 1996;87:59-64.
3. Kim YT, Thomas NF, Kessis TD, Wilkinson EJ, Hedrick L, Cho KR. p53 mutations and clonality in vulvar carcinomas and squamous hyperplasias: evidence suggesting that squamous hyperplasias do not serve as direct precursors of human papillomavirus-negative vulvar carcinomas. Hum Pathol 1996;27:389-95.
4. Hording U, Junge J, Daugaard S, Lundvall F, Poulsen H, Bock JE. Vulvar squamous cell carcinoma and papillomaviruses: indications for two different etiologies. Gynecol Oncol 1994; 52:241-6.
5. Hording U, Junge J, Poulsen H, Lundvall F. Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential. Gynecol Oncol 1995;56:276-9.
6. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
7. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. Clonal p53 mutations in primary cervical cancer: association with human papillomavirus negative tumours. Lancet 1992;339:1070-3.
8. Crook T, Wrede D, Vousden KH. p53 mutation in HPV negative human cervical cell lines. Oncogene 1991;6:873-5.
9. Paquette RL, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW, et al. Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 1993;72:1272-80.
10. Scheffner M, Takahashi T, Huibregtse JM, Minna JD, Howley PM. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J Virol 1992;66:5100-5.
11. Pilotti S, Donghi R, D'Amato L, Giarola M, Longoni A, Della Torre G, et al. Papillomavirus, p53 alteration and primary carcinoma of the vulva. Eur J Cancer 1993;29A:924-5.
12. Chen TM, Chen CA, Hsieh CY, Chang DY, Chen YH, Defendi V. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells. Oncogene 1993;8:1511-8.
13. Busby-Earle RMC, Steel CM, Williams ARW, Cohen B, Bird CC. Papillomaviruses, p53 and cervical cancer. Lancet 1992; 339:1350.
14. Mittal KR, Lin O, Chan W, Goswami S, Demopoulos RI. Cervical squamous dysplasias and carcinomas with immunodetectable p53 frequently contain HPV. Gynecol Oncol 1995; 58:289-94.
15. Furihata M, Inoue M, Ohtsuki Y, Hashimoto H, Terao N, Fujita Y. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res 1993;53:4823-7.
16. Kohlberger P, Kainz Ch, Breitenecker G, Gitsch G, Sliutz G, Kölbl H, et al. Prognostic value of immunohistochemically detected p53 expression in vulvar carcinoma. Cancer 1995;76:1786-9.
17. Report of the ISSVD Terminology committee. Proceedings of the Eighth World Congress, Stockholm, Sweden. J Reprod Med 1986;31:973-4.
18. Wright DK, Manos MM. Sample preparation from paraffin-embedded tissues. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols: a guide to methods and applications. San Diego: Academic Press, 1990:153-8.
19. Snijders PJF, van den Brule AJC, Schrijnemakers HFJ, Snow G, Meijer CJLM, Walboomers JMM. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol 1990;71:173-81.
20. Ponte P, Ng SY, Engel J, Gunning P, Kedes L. Evolutionary conservation in the untranslated regions of actin mRNA: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 1984;12:1687-96.
21. Bosari S, Viale G. The clinical significance of p53 aberrations in human tumours. Virchows Arch 1995;427:229-41.
22. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994;57:1-9.
23. Tervahauta AI, Syrjänen SM, Väyreynen M, Saastamoinen J, Syrjänen KJ. Expression of p53 protein related to the presence of human papillomavirus (HPV) DNA in genital carcinomas and precancer lesions. Anticancer Res 1993;13:1107-12.
24. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Löning T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer 1995;63:639-45.
25. Busby-Earle RMC, Steel CM, Williams ARW, Cohen B, Bird CC. p53 mutations in cervical carcinogenesis-low frequency and lack of correlation with human papillomavirus status. Br J Cancer 1994;69:732-7.
26. Akasofu M, Oda Y. Immunohistochemical detection of p53 in cervical epithelial lesions with or without infection of human papillomavirus types 16 and 18. Virchows Arch 1995; 425:593-602.
27. Harmsel B, van Belkum A, Quint W, Pronk A, Kuijpers J, Ramaekers F, et al p53 and human papilloma virus type 16 in cervical intraepithelial neoplasia and carcinoma. Int J Gynecol Pathol 1995;14:125-33.
28. Jeffers MD, Richmond J, Farquharson M, McNicol AM. p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium. J Clin Pathol 1994;47:1073-6.
29. Helland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, et al. Genetic alterations of TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 1993;171:105-14.
30. Bosari S, Roncalli M, Viale G, Bossi P, Coggi G. p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. J Pathol 1993;169:425-30.